Search

• GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over

  Media

  Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses, with a two-to-six month interval between doses.

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-receives-positive-opinion-from-the-chmp-in-europe-for-the-prevention-of-shingles-in-adults-aged-50-and-over/

  First published: 26 January 2018

• Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over

  Media

  GSK announced the EC has approved Shingrix for the prevention of shingles & PHN in adults aged 50 years or older.

  https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over/

  First published: 23 March 2018

• CHMP recommend Nucala (mepolizumab) for the treatment of severe eosinophilic asthma paediatric patients in Europe

  Media

  GSK announced, EMA's CHMP is recommending Nucala as an add-on treatment for severe refractory eosinophilic asthma in paediatric patients.

  https://www.gsk.com/en-gb/media/press-releases/chmp-recommend-nucala-mepolizumab-for-the-treatment-of-severe-eosinophilic-asthma-paediatric-patients-in-europe/

  First published: 27 July 2018

• GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium

  Media

  Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-efficacy-data-of-dostarlimab-in-mismatch-repair-deficient-dmmr-solid-cancers-at-asco-gastrointestinal-cancers-symposium/

  First published: 16 January 2021

• GSK and Save the Children call for developing country innovations to enter $1 million award

  Media

  GSK and Save the Children today launched their fourth annual $1 million Healthcare Innovation Award.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-call-for-developing-country-innovations-to-enter-1-million-award/

  First published: 07 July 2016

• GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and efficacy of gene therapy for children with ADA-SCID

  Media

  GSK today announced the publication in BLOOD of the long-term safety and efficacy data from an analysis of 18 children with ADA-SCID

  https://www.gsk.com/en-gb/media/press-releases/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-publication-of-pivotal-safety-and-efficacy-of-gene-therapy-for-children-with-ada-scid/

  First published: 25 May 2016

• European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries

  Media

  Milestone for GSK and Save the Children partnership and its mission to help save the lives of children in the world’s poorest communities

  https://www.gsk.com/en-gb/media/press-releases/european-agency-endorses-antiseptic-gel-developed-through-gsk-and-save-the-children-partnership-for-newborn-umbilical-cord-infections-in-developing-countries/

  First published: 29 April 2016

• ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries

  Media

  Follows announcement by majority shareholder GSK to expand graduated approach to patents and intellectual property (IP)

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries/

  First published: 25 April 2016

• GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over

  Media

  Shingrix is a recombinant subunit adjuvanted vaccine given intramuscularly in two doses.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-approval-of-shingrix-in-china-for-prevention-of-shingles-in-adults-aged-50-and-over/

  First published: 23 May 2019

• US Food and Drug Administration accepts New Drug Application for daprodustat

  Media

  US FDA regulatory submission acceptance is the third major regulatory milestone for daprodustat

  https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-accepts-new-drug-application-for-daprodustat/

  First published: 19 April 2022